PACIRA BIOSCIENCES, INC. Operating Lease, Payments
PACIRA BIOSCIENCES, INC. (PCRX) reported Operating Lease, Payments of $6.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. operating lease, payments for the quarter ending 2026-06-30 was $3.22M, a 0.75% increase year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, payments for the quarter ending 2026-03-31 was $3.25M, a 0.49% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, payments for the quarter ending 2025-12-31 was $3.20M, a 3.21% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, payments for the quarter ending 2025-09-30 was $3.19M, a 2.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, payments for fiscal 2025 was $12.85M, a 1.09% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. operating lease, payments for fiscal 2024 was $12.99M, a 8.89% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. operating lease, payments for fiscal 2023 was $14.26M, a 0.68% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. operating lease, payments for fiscal 2022 was $14.36M, a 12.97% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.47M 10-Q · filed 2026-08-04 | $9.66M derived: sum of 3 quarters · filed 2026-08-04 | $12.86M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.25M 10-Q · filed 2026-04-30 | $6.45M derived: sum of 2 quarters · filed 2026-04-30 | $9.64M derived: sum of 3 quarters · filed 2026-04-30 | $12.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.39M derived: sum of 2 quarters · filed 2026-02-26 | $9.59M derived: sum of 3 quarters · filed 2026-08-04 | $12.85M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.39M derived: sum of 2 quarters · filed 2026-08-04 | $9.65M 10-Q · filed 2025-11-06 | $12.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.46M 10-Q · filed 2026-08-04 | $9.76M derived: sum of 3 quarters · filed 2026-08-04 | $13.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.26M 10-Q · filed 2026-04-30 | $6.57M derived: sum of 2 quarters · filed 2026-04-30 | $9.82M derived: sum of 3 quarters · filed 2026-04-30 | $13.03M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.56M derived: sum of 2 quarters · filed 2026-02-26 | $9.77M derived: sum of 3 quarters · filed 2026-02-26 | $12.99M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.47M derived: sum of 2 quarters · filed 2025-11-06 | $9.69M 10-Q · filed 2025-11-06 | $12.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $6.43M 10-Q · filed 2025-08-05 | $9.63M derived: sum of 3 quarters · filed 2026-02-26 | $13.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.22M 10-Q · filed 2025-05-08 | $6.42M derived: sum of 2 quarters · filed 2026-02-26 | $10.15M derived: sum of 3 quarters · filed 2026-02-26 | $13.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.93M derived: sum of 2 quarters · filed 2026-02-26 | $10.50M derived: sum of 3 quarters · filed 2026-02-26 | $14.26M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.29M derived: sum of 2 quarters · filed 2024-11-06 | $11.05M 10-Q · filed 2024-11-06 | $15.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $7.33M 10-Q · filed 2024-07-30 | $11.76M derived: sum of 3 quarters · filed 2025-02-27 | $15.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.76M 10-Q · filed 2024-05-07 | $8.20M derived: sum of 2 quarters · filed 2025-02-27 | $11.48M derived: sum of 3 quarters · filed 2025-02-27 | $14.84M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.72M derived: sum of 2 quarters · filed 2025-02-27 | $11.08M derived: sum of 3 quarters · filed 2025-02-27 | $14.36M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $6.64M derived: sum of 2 quarters · filed 2023-11-02 | $9.92M 10-Q · filed 2023-11-02 | $12.76M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $6.64M 10-Q · filed 2023-08-02 | $9.48M derived: sum of 3 quarters · filed 2024-02-29 | $12.17M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $3.28M 10-Q · filed 2023-05-03 | $6.12M derived: sum of 2 quarters · filed 2024-02-29 | $8.81M derived: sum of 3 quarters · filed 2024-02-29 | $11.39M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.53M derived: sum of 2 quarters · filed 2024-02-29 | $8.11M derived: sum of 3 quarters · filed 2024-02-29 | $12.71M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.27M derived: sum of 2 quarters · filed 2022-11-03 | $9.87M 10-Q · filed 2022-11-03 | $12.96M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $7.18M 10-Q · filed 2022-08-03 | $10.27M derived: sum of 3 quarters · filed 2023-02-28 | $13.02M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $4.60M 10-Q · filed 2022-05-04 | $7.70M derived: sum of 2 quarters · filed 2023-02-28 | $10.44M derived: sum of 3 quarters · filed 2023-02-28 | $18.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.84M derived: sum of 2 quarters · filed 2023-02-28 | $14.35M derived: sum of 3 quarters · filed 2023-02-28 | $14.35M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $11.25M derived: sum of 2 quarters · filed 2021-11-03 | $11.25M 10-Q · filed 2021-11-03 | $16.11M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $8.50M 10-Q · filed 2020-08-06 | $8.50M 10-Q · filed 2021-08-03 | $13.36M derived: sum of 3 quarters · filed 2022-02-28 | $15.49M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.76M 10-Q · filed 2021-05-04 | $4.86M derived: sum of 2 quarters · filed 2022-02-28 | $6.98M derived: sum of 3 quarters · filed 2022-02-28 | $10.11M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.22M derived: sum of 2 quarters · filed 2022-02-28 | $7.35M derived: sum of 3 quarters · filed 2022-02-28 | $7.35M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $5.25M derived: sum of 2 quarters · filed 2020-10-30 | $5.25M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $3.12M 10-Q · filed 2020-08-06 | $3.12M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $2.05M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |